EHTH · eHealth, Inc.
Market Cap
$24.20M
Shares
32.03M
Volume · Oct 5
419.63K
Avg daily vol (3M)
303.3K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$0.67
Open$0.70
Day$0.67–0.71
52W close$0.67–5.65
Avg vol 30d358K
Short int414K · 1.3% float · 1.0d
Short vol47%
Last earningsAug 4, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 5
Up next
Next earnings call
Nov 3, 2026
Est · unconfirmed
· in 4 wks
filed Aug 5, 2026
call held Aug 4, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$501.69M
Trailing 12 months
Net income (TTM)
$27.18M
Trailing 12 months
Revenue growth YoY
-44.8%
Year over year
Operating margin
10.8%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-129.9%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.5%
Year over year · more shares
Price change (1Y)
-84.2%
Trailing year
Short interest
1.3%
Latest settlement · 1.0 days to cover
AI Brief
Q2 FY26 earnings call · Aug 4, 2026
Q2 FY26
TL;DR. eHealth (EHTH) reported Q2 2026 revenue of $33.6M, down 45% YoY, as it deliberately reduced marketing spend outside major enrollment periods to focus advisors on its newly launched lifetime advisory model. The company reiterated full-year 2026 guidance ranges for revenue, GAAP net income, adjusted EBITDA and operating cash flow, while updating net adjustment (tail) revenue guidance to $16M–$20M (from $8M–$20M) to reflect the $7.6M of Q2 tail revenue.
Bullish
- + Reiterated full-year 2026 guidance ranges for revenue, GAAP net income, adjusted EBITDA and operating cash flow and raised net adjustment revenue outlook to $16M–$20M from $8M–$20M.
- + Operating cash flow improved $36.2M year-over-year in Q2 to $(5.0)M vs. $(41.2)M, supporting meaningful YoY operating cash flow improvement for the year.
- + Q2 ancillary product cross-sell rates doubled YoY and other member engagement metrics improved, providing early validation of the new lifetime advisory model launched in Q2.
- + Non-GAAP operating expenses declined 25% YoY in Q2, on track for >$60M variable and ~$30M fixed annual cost savings vs. prior year.
- + Positive net adjustment (tail) revenue of $7.6M in Q2, bringing cumulative tail revenue to $284M since 2018, and commissions receivable grew 10% YoY to $1.0B.
Bearish
- − Q2 total revenue fell 45% YoY to $33.6M and Medicare segment revenue fell 45% YoY to $31.8M, driven by lower Medicare enrollment volume and lower tail revenue.
- − GAAP net loss widened to $(23.6)M from $(17.4)M and adjusted EBITDA loss deepened to $(21.8)M from $(14.1)M year-over-year.
- − Management expects an even greater YoY decline in Q3 enrollment volume and revenue than the 45% Q2 marketing cut, as the majority of marketing spend is deferred to Q4 AEP.
- − Medicare segment gross profit fell 69% YoY to $6.0M from $19.1M, with $10.0M of the decline attributable to lower tail revenue.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Strong Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Excellent
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−64%
below
Price vs 50-day avg
−38%
below
RSI (14)
18
oversold
MACD trend
Negative
52-week position
0%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−29%
trailing
6-month return
−55%
trailing
YTD return
−85%
this year
Relative strength
−67%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.29% of float · ▼ -27.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Squeeze score
37
low risk · 0–100
Fundamentals
Revenue growth
+32%
Y/Y
Gross margin
96%
contracting
EPS growth
+71%
Y/Y
Free cash flow
$-27.6M
Buyback
$50.0M
authorized
Quant / Vol
risk profile
Volatility
93%
annualized · 1-yr
Max drawdown
−88%
past year
ATR
9.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Aug 4, 2026
Total revenue
· full year ending December 31, 2026
Initiated
$405M – $445M
prior FY $554.01M
midpoint −23.3% Y/Y
GAAP net income
· full year ending December 31, 2026
Initiated
$8M – $25M
Adjusted EBITDA
· full year ending December 31, 2026
Initiated
$55M – $75M
Operating cash flow
· full year ending December 31, 2026
Initiated
$-10M – $12M
Positive net adjustment revenue
· full year ending December 31, 2026
Initiated
$16M – $20M
Guided vs delivered
· last 6 settled
Total revenue
full year ending December 31, 2024
guided $470M – $495M
$532.41M
Beat +10.3%
Total revenue
full year ending December 31, 2023
guided $439M – $459M
$452.87M
In line
Total revenue
2021 annual
guided $535M – $575M
$538.2M
In line
GAAP net income per diluted share
2021
guided $1.53 – $2.08
$-4.59
Miss −354.3%
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−64%
Bearish
Price vs 50-day avg
−38%
Bearish
RSI (14)
18
Neutral
MACD trend
Negative
Bearish
52-week position
0%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow
Distributing
-1% holders QoQ · +23 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
1.29% of float · ▼ -27.4% MoM · 1.0 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
105 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 0%
Range high $6
vs 200-day avg -64%
vs 50-day avg -38%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Ancillary approved members | 10,737 | Three Months Ended June 30, 2026 filing | — |
| CC&E cost per IFP-equivalent approved member | $490 | Three Months Ended June 30, 2026 filing | — |
| CC&E cost per MA-equivalent approved member | $941 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Dental | $126 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Medicare Advantage | $921 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Medicare Supplement | $1,661 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Non-Qualified Health Plans | $302 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Qualified Health Plans | $275 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Short-term | $127 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Small Business | $344 | Three Months Ended June 30, 2026 filing | — |
| Constrained LTV of commissions per approved member - Vision | $81 | Three Months Ended June 30, 2026 filing | — |
| Individual and Family approved members | 1,487 | Three Months Ended June 30, 2026 filing | — |
| Medicare Advantage approved members | 16,780 | Three Months Ended June 30, 2026 filing | — |
| Medicare Part D approved members | 281 | Three Months Ended June 30, 2026 filing | — |
| Medicare Supplement approved members | 958 | Three Months Ended June 30, 2026 filing | — |
| Small Business approved members | 986 | Three Months Ended June 30, 2026 filing | — |
| Total acquisition cost per IFP-equivalent approved member | $574 | Three Months Ended June 30, 2026 filing | — |
| Total acquisition cost per MA-equivalent approved member | $1,266 | Three Months Ended June 30, 2026 filing | — |
| Total Approved Members | 31,229 | Three Months Ended June 30, 2026 filing | — |
| Total Medicare approved members | 18,019 | Three Months Ended June 30, 2026 filing | — |
| Variable marketing cost per MA-equivalent approved member | $325 | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Insurance Brokers — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
EHTH
this stock
eHealth, Inc.
|
$24.20M | -85.4% | +31.8% | — | 1.3% |
|
MRSH
Marsh & Mclennan Companies, Inc.
|
$81.66B | -8.3% | +10.3% | 20.9 | 1.2% |
|
AJG
Arthur J. Gallagher & Co.
|
$58.90B | -12.6% | +10.1% | 38.1 | 2.5% |
|
AON
Aon plc
|
$58.11B | -23.6% | +7.7% | 15.1 | 1.7% |
|
WTW
Willis Towers Watson PLC
|
$27.30B | -12.2% | -2.2% | 18.2 | 2.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| EHTH | -11.8% | -29.5% | -54.7% | -5.6% | -85.4% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -11.6% | -29.0% | -66.9% | -6.6% | -98.3% |
Capital returns
Buyback program
· as of Mar 31, 2014
Authorized
$50.00M
Spent (derived)
—
Remaining
—
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.